Tissue-specific mRNA delivery and prime editing with peptide-ionizable lipid nanoparticles

  • Nat Mater. 2026 Jan;25(1):133-145. doi: 10.1038/s41563-025-02320-9.
Yi Lin  #  1 Mengyao Li  #  2  3  4 Zijin Luo  2  3  4 Yanan Meng  2  3  4 Yan Zong  1 Hongyu Ren  2  3  4 Xiaolu Yu  2  3  4 Xiaoqiong Tan  1 Fan Liu  2  3  4 Tuo Wei  5  6  7 Qiang Cheng  8  9
Affiliations
  • 1. Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, China.
  • 2. State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
  • 3. Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.
  • 4. University of Chinese Academy of Sciences, Beijing, China.
  • 5. State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China. [email protected].
  • 6. Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China. [email protected].
  • 7. University of Chinese Academy of Sciences, Beijing, China. [email protected].
  • 8. Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, China. [email protected].
  • 9. Beijing Advanced Center of RNA Biology (BEACON), Peking University, Beijing, China. [email protected].
  • # Contributed equally.
Abstract

Lipid nanoparticles for mRNA delivery and gene editing have the potential to transform the current therapeutic landscape. Nonetheless, a major bottleneck using this technology is the difficulty in achieving cell- and tissue-specific delivery and avoiding liver accumulation. Here we report the rational design of peptide ionizable lipids to assemble lipid nanoparticles with organ-selective mRNA delivery. Structure-activity and structure-selectivity relationship analyses enable us to obtain a general and predictable strategy for peptide ionizable lipid design. By incorporating artificial ionizable and natural Amino acids and/or Functional Molecules into peptide ionizable lipids, we create lipid nanoparticles with tissue-specific targeting, including the lungs, liver, spleen, thymus and bone. In particular, lipid nanoparticles containing peptide lipids targeting the liver show comparable efficacy and safety compared with FDA-approved formulations. Furthermore, lipid nanoparticles with peptide lipids achieve the efficient co-delivery of PEmax mRNA and engineered prime editing guide RNA for prime editing of the liver and lungs. Overall, our platform offers a predictable methodology for the rational design of tissue-targeting lipid nanoparticles that might aid the development of improved mRNA-based gene editing therapeutics.

Products